Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021

We compared PCR results from SARS-CoV-2-positive patients tested in the community in France from 14 June to 30 July 2021. In asymptomatic individuals, Cq values were significantly higher in fully vaccinated than non-fully vaccinated individuals (effect size: 1.7; 95% CI: 1-2.3; p 

Saved in:
Bibliographic Details
Published in:Euro surveillance : bulletin européen sur les maladies transmissibles 2021-09, Vol.26 (37), p.1
Main Authors: Blanquart, François, Abad, Clémence, Ambroise, Joëvin, Bernard, Mathieu, Cosentino, Gina, Giannoli, Jean-Marc, Débarre, Florence
Format: Article
Language:English
Subjects:
Antibodies
COVID-19
COVID-19 vaccines
Emerging diseases
France
Health surveillance
Human health and pathology
Humans
Immunization
Immunology
Infectious diseases
Life Sciences
Rapid Communication
Santé publique et épidémiologie
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vaccinology
Viral infections
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53
cites cdi_FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53
container_end_page
container_issue 37
container_start_page 1
container_title Euro surveillance : bulletin européen sur les maladies transmissibles
container_volume 26
creator Blanquart, François
Abad, Clémence
Ambroise, Joëvin
Bernard, Mathieu
Cosentino, Gina
Giannoli, Jean-Marc
Débarre, Florence
description We compared PCR results from SARS-CoV-2-positive patients tested in the community in France from 14 June to 30 July 2021. In asymptomatic individuals, Cq values were significantly higher in fully vaccinated than non-fully vaccinated individuals (effect size: 1.7; 95% CI: 1-2.3; p 
doi_str_mv 10.2807/1560-7917.ES.2021.26.37.2100824
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8447828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2574385689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53</originalsourceid><addsrcrecordid>eNpdkl1v0zAUhiMEYmPwF5AlLgBpCf5M4htQVToGqoREgVvLcezFI7GL7RT1L_ErSWipxq6Odfyc93zozbKXCBa4htUbxEqYVxxVxWpTYIhRgcuCVAVGENaYPsjOT8TDO--z7EmMtxBSAjl-nJ0RyghBiJ9nv5edDFIlHWyUyXoHvAE7qZR1GjRByx-pC3686YB1RquZiDOyWXzZ5Ev_Pcfgve6TBNK1YNFvOzlVBytdin9Tv2zqrMs7HxPY2SB70HvZgnbv5GBVnFRB6jRQfhhGZ9P-ElwF6ZS-BJ_GaYLkp9jvwbzq0-yRkX3Uz47xIvt2tfq6vM7Xnz98XC7WuWKQpJxT3ihjCIfESG1qYxCmmNScYsQYg7ThZd1AoziUpS4lbxpGVcsayktuGkYusrcH3e3YDLpV2qVpbrENdpBhL7y04v8fZztx43eiprSqcT0JvD4IdPfKrhdrMecgIRWsKrZDE_vq2Cz4n6OOSQw2Kt330mk_RoFZRUnNyppP6It76K0fg5tOMVOME4QZnqh3B0oFH2PQ5jQBgmL2kJhdIWZXiNVGzIcVuBSkEkcPTQrP7-5_qv9nGvIHxTjEHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2575931252</pqid></control><display><type>article</type><title>Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021</title><source>Open Access: PubMed Central</source><creator>Blanquart, François ; Abad, Clémence ; Ambroise, Joëvin ; Bernard, Mathieu ; Cosentino, Gina ; Giannoli, Jean-Marc ; Débarre, Florence</creator><creatorcontrib>Blanquart, François ; Abad, Clémence ; Ambroise, Joëvin ; Bernard, Mathieu ; Cosentino, Gina ; Giannoli, Jean-Marc ; Débarre, Florence</creatorcontrib><description>We compared PCR results from SARS-CoV-2-positive patients tested in the community in France from 14 June to 30 July 2021. In asymptomatic individuals, Cq values were significantly higher in fully vaccinated than non-fully vaccinated individuals (effect size: 1.7; 95% CI: 1-2.3; p &lt; 10-6). In symptomatic individuals and controlling for time since symptoms, the difference vanished (p = 0.26). Infections with the Delta variant had lower Cq values at symptom onset than with Alpha (effect size: -3.32; 95% CI: -4.38 to -2.25; p &lt; 10-6).</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>EISSN: 1025-496X</identifier><identifier>DOI: 10.2807/1560-7917.ES.2021.26.37.2100824</identifier><identifier>PMID: 34533119</identifier><language>eng</language><publisher>Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</publisher><subject>Antibodies ; COVID-19 ; COVID-19 vaccines ; Emerging diseases ; France ; Health surveillance ; Human health and pathology ; Humans ; Immunization ; Immunology ; Infectious diseases ; Life Sciences ; Rapid Communication ; Santé publique et épidémiologie ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines ; Vaccinology ; Viral infections ; Viral Load</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2021-09, Vol.26 (37), p.1</ispartof><rights>Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Sep 16, 2021</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>This article is copyright of the authors or their affiliated institutions, 2021. 2021 The authors or their affiliated institutions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53</citedby><cites>FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53</cites><orcidid>0000-0003-0591-2466 ; 0000-0003-2497-833X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447828/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447828/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27898,27899,53763,53765</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34533119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-03370775$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Blanquart, François</creatorcontrib><creatorcontrib>Abad, Clémence</creatorcontrib><creatorcontrib>Ambroise, Joëvin</creatorcontrib><creatorcontrib>Bernard, Mathieu</creatorcontrib><creatorcontrib>Cosentino, Gina</creatorcontrib><creatorcontrib>Giannoli, Jean-Marc</creatorcontrib><creatorcontrib>Débarre, Florence</creatorcontrib><title>Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>We compared PCR results from SARS-CoV-2-positive patients tested in the community in France from 14 June to 30 July 2021. In asymptomatic individuals, Cq values were significantly higher in fully vaccinated than non-fully vaccinated individuals (effect size: 1.7; 95% CI: 1-2.3; p &lt; 10-6). In symptomatic individuals and controlling for time since symptoms, the difference vanished (p = 0.26). Infections with the Delta variant had lower Cq values at symptom onset than with Alpha (effect size: -3.32; 95% CI: -4.38 to -2.25; p &lt; 10-6).</description><subject>Antibodies</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Emerging diseases</subject><subject>France</subject><subject>Health surveillance</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Rapid Communication</subject><subject>Santé publique et épidémiologie</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><subject>Vaccinology</subject><subject>Viral infections</subject><subject>Viral Load</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><issn>1025-496X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkl1v0zAUhiMEYmPwF5AlLgBpCf5M4htQVToGqoREgVvLcezFI7GL7RT1L_ErSWipxq6Odfyc93zozbKXCBa4htUbxEqYVxxVxWpTYIhRgcuCVAVGENaYPsjOT8TDO--z7EmMtxBSAjl-nJ0RyghBiJ9nv5edDFIlHWyUyXoHvAE7qZR1GjRByx-pC3686YB1RquZiDOyWXzZ5Ev_Pcfgve6TBNK1YNFvOzlVBytdin9Tv2zqrMs7HxPY2SB70HvZgnbv5GBVnFRB6jRQfhhGZ9P-ElwF6ZS-BJ_GaYLkp9jvwbzq0-yRkX3Uz47xIvt2tfq6vM7Xnz98XC7WuWKQpJxT3ihjCIfESG1qYxCmmNScYsQYg7ThZd1AoziUpS4lbxpGVcsayktuGkYusrcH3e3YDLpV2qVpbrENdpBhL7y04v8fZztx43eiprSqcT0JvD4IdPfKrhdrMecgIRWsKrZDE_vq2Cz4n6OOSQw2Kt330mk_RoFZRUnNyppP6It76K0fg5tOMVOME4QZnqh3B0oFH2PQ5jQBgmL2kJhdIWZXiNVGzIcVuBSkEkcPTQrP7-5_qv9nGvIHxTjEHQ</recordid><startdate>20210916</startdate><enddate>20210916</enddate><creator>Blanquart, François</creator><creator>Abad, Clémence</creator><creator>Ambroise, Joëvin</creator><creator>Bernard, Mathieu</creator><creator>Cosentino, Gina</creator><creator>Giannoli, Jean-Marc</creator><creator>Débarre, Florence</creator><general>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</general><general>European Centre for Disease Prevention and Control</general><general>European Centre for Disease Prevention and Control (ECDC)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0591-2466</orcidid><orcidid>https://orcid.org/0000-0003-2497-833X</orcidid></search><sort><creationdate>20210916</creationdate><title>Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021</title><author>Blanquart, François ; Abad, Clémence ; Ambroise, Joëvin ; Bernard, Mathieu ; Cosentino, Gina ; Giannoli, Jean-Marc ; Débarre, Florence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Emerging diseases</topic><topic>France</topic><topic>Health surveillance</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Rapid Communication</topic><topic>Santé publique et épidémiologie</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><topic>Vaccinology</topic><topic>Viral infections</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blanquart, François</creatorcontrib><creatorcontrib>Abad, Clémence</creatorcontrib><creatorcontrib>Ambroise, Joëvin</creatorcontrib><creatorcontrib>Bernard, Mathieu</creatorcontrib><creatorcontrib>Cosentino, Gina</creatorcontrib><creatorcontrib>Giannoli, Jean-Marc</creatorcontrib><creatorcontrib>Débarre, Florence</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blanquart, François</au><au>Abad, Clémence</au><au>Ambroise, Joëvin</au><au>Bernard, Mathieu</au><au>Cosentino, Gina</au><au>Giannoli, Jean-Marc</au><au>Débarre, Florence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2021-09-16</date><risdate>2021</risdate><volume>26</volume><issue>37</issue><spage>1</spage><pages>1-</pages><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><eissn>1025-496X</eissn><abstract>We compared PCR results from SARS-CoV-2-positive patients tested in the community in France from 14 June to 30 July 2021. In asymptomatic individuals, Cq values were significantly higher in fully vaccinated than non-fully vaccinated individuals (effect size: 1.7; 95% CI: 1-2.3; p &lt; 10-6). In symptomatic individuals and controlling for time since symptoms, the difference vanished (p = 0.26). Infections with the Delta variant had lower Cq values at symptom onset than with Alpha (effect size: -3.32; 95% CI: -4.38 to -2.25; p &lt; 10-6).</abstract><cop>Sweden</cop><pub>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</pub><pmid>34533119</pmid><doi>10.2807/1560-7917.ES.2021.26.37.2100824</doi><orcidid>https://orcid.org/0000-0003-0591-2466</orcidid><orcidid>https://orcid.org/0000-0003-2497-833X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1560-7917
ispartof Euro surveillance : bulletin européen sur les maladies transmissibles, 2021-09, Vol.26 (37), p.1
issn 1560-7917
1025-496X
1560-7917
1025-496X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8447828
source Open Access: PubMed Central
subjects Antibodies
COVID-19
COVID-19 vaccines
Emerging diseases
France
Health surveillance
Human health and pathology
Humans
Immunization
Immunology
Infectious diseases
Life Sciences
Rapid Communication
Santé publique et épidémiologie
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vaccinology
Viral infections
Viral Load
title Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T19%3A41%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterisation%20of%20vaccine%20breakthrough%20infections%20of%20SARS-CoV-2%20Delta%20and%20Alpha%20variants%20and%20within-host%20viral%20load%20dynamics%20in%20the%20community,%20France,%20June%20to%20July%202021&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Blanquart,%20Fran%C3%A7ois&rft.date=2021-09-16&rft.volume=26&rft.issue=37&rft.spage=1&rft.pages=1-&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/1560-7917.ES.2021.26.37.2100824&rft_dat=%3Cproquest_pubme%3E2574385689%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-949bcff3903faef8ff124238942155504b968b0fc90a6e6a9bb54cd5b4969fb53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2575931252&rft_id=info:pmid/34533119&rfr_iscdi=true